TABLE 6.
Multivariate analysis of PFS for EPSILoN
| Covariate | Category | Multivariate analysis | |
|---|---|---|---|
| HR (95% CI) | p value | ||
| Clinical stage | IV | 1.255 (0.886–1.777) | 0.201 |
| ECOG PS | 2–3 | 2.199 (1.356–3.565) | 0.001* |
| Smoking status | Former/current | 0.759 (0.601–0.959) | 0.021* |
| Number of metastatic sites | ≥3 | 1.263(0.894–1.785) | 0.186 |
| Line of immunotherapy | ≥3 | 1.245 (0.979–1.584) | 0.074 |
| Liver metastases | Yes | 1.677 (1.200–2.343) | 0.002* |
| Bone metastases | Yes | 0.910 (0.678–1.222) | 0.531 |
| NLR | ≥4 | 2.455 (1.875–3.214) | < 0.001* |
| LDH | >1.5*ULN | 2.715 (1.904–3.872) | <0.001* |
| PLR | ≥160 | 1.074 (0.820–1.408) | 0.604 |
Abbreviations: dNLR, derived neutrophil‐to‐lymphocyte ratio; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; NLR, neutrophil‐to‐lymphocyte ratio; PFS, progression‐free survival; PLR, platelet‐to‐lymphocyte ratio.
*
means p < 0.05.